A META-ANALYSIS OF PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME TREATMENT IN CANCER PATIENTS WITH FEBRILE NEUTROPENIA

被引:0
作者
Zhang Weidong [1 ]
Xiao Chun [2 ]
Zhou Sixin [3 ]
Wang Rui [1 ]
Wang Li [1 ]
Jia Liping [1 ]
Ma Jinqiu [1 ]
Wang Na [1 ]
机构
[1] First Hosp Qinhuangdao, Qinhuangdao 066000, Peoples R China
[2] PLA Rocket Force, Gen Hosp, Dept Gen Surg, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China
来源
BIOSCIENCE JOURNAL | 2016年 / 32卷 / 06期
关键词
Meta-analysis; Piperacillin/Tazobactam; Cefepime; Febrile neutropenia; Cancer; STEM-CELL TRANSPLANTATION; EMPIRICAL-TREATMENT; OPEN-LABEL; MONOTHERAPY; TAZOBACTAM; MULTICENTER; MANAGEMENT; THERAPY; FEVER; CHEMOTHERAPY;
D O I
暂无
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Febrile neutropenia (FN) causes a major threat to cancer patients after chemotherapy. Broad-spectrum antibiotic treatment is a well-established practice for febrile neutropenia. Piperacillin/Tazobactam (P/T) is the frequently used antibiotic in most of FN cases, whereas the use of cefepime remains unclear regarding its potential risk. However, little systematic analysis has been conducted about comparison between these two drugs. Thus, we undertook this meta-analysis to compare these two monotherapies for febrile neutropenia. Through searching Pubmed, Google scholar, Medline databases, EMBASE, OvidSP, ScienceDirect, Web of science, and China Journal Net (CJN) databases, we used the keywords "(Piperacillin/Tazobactam AND cefepime) AND (febrile neutropenia) AND (cancer or tumor)". Only studies with randomized controlled trials were included in the meta-analysis. We screened out a total number of seven clinical trials. This meta-analysis supported that P/T treatment was superior to cefepime treatment based on the average OR comparison, without statistical significance (OR = 1.27, 95% confidence interval = 0.98 to 1.64, p = 0.07). We further divided the seven studies into two subgroups based on age and treatment time. The young group (age <= 19) showed no significant difference (OR = 1.10, p = 0.65). While the old group (age > 19) showed that P/T treatment was better than cefepime with statistical difference (OR = 1.44, p = 0.05). The short-term group (time <= 3 ds) showed P/T treatment was better than cefepime with statistical difference (OR = 1.40, p = 0.05). While in the long-term group (time > 5 ds), there was no significant difference between P/T and cefepime therapy (OR = 1.06, p = 0.79) Asymmetry in Funnel plots indicated no publication bias (CHI2 = 1.47, I-2 = 0%, and p-value = 0.96) in this meta-analysis. It would be a good clinical trial to use P/T treatment to cure FN in cancer patients compared with cefepime treatment, especially in adult patients or patients with a short-term treatment period. This meta-analysis is practically important during antibiotic treatment in FN management.
引用
收藏
页码:1669 / 1678
页数:10
相关论文
共 50 条
[31]   Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day [J].
Ryoji Kobayashi ;
Hirozumi Sano ;
Satoru Matsushima ;
Daiki Hori ;
Masato Yanagi ;
Koya Kodama ;
Daisuke Suzuki ;
Kunihiko Kobayashi .
International Journal of Hematology, 2021, 113 :430-435
[32]   Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults [J].
Roohullah, A. ;
Moniwa, A. ;
Wood, C. ;
Humble, M. ;
Balm, M. ;
Carter, J. ;
Weinkove, R. .
INTERNAL MEDICINE JOURNAL, 2013, 43 (10) :1151-1154
[33]   Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia [J].
Kim, Bo-Guen ;
Kang, Danbee ;
Min, Kyung Hoon ;
Cho, Juhee ;
Jeon, Kyeongman .
ANTIBIOTICS-BASEL, 2023, 12 (06)
[34]   Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia [J].
J. Montalar ;
A. Segura ;
C. Bosch ;
A. Galan ;
O. Juan ;
C. Molins ;
V. Giner ;
J. Aparicio .
Medical Oncology, 2002, 19 :161-166
[35]   Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia [J].
Montalar, J ;
Segura, A ;
Bosch, C ;
Galan, A ;
Juan, O ;
Molins, C ;
Giner, V ;
Aparicio, J .
MEDICAL ONCOLOGY, 2002, 19 (03) :161-166
[36]   Efficacy and safety of empirical treatment with piperacillin/tazobactan as monotherapy in episodes of neutropenia and fever in children with cancer: systematic review and meta-analysis [J].
Teresa Rosanova, Maria ;
Cuellar-Pompa, Leticia ;
Lede, Roberto .
REVISTA CHILENA DE INFECTOLOGIA, 2021, 38 (04) :488-494
[37]   Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies [J].
Yildirim, I. ;
Aytac, S. ;
Ceyhan, M. ;
Cetin, M. ;
Tuncer, M. ;
Cengiz, A. B. ;
Secmeer, G. ;
Yetgin, S. .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2008, 25 (04) :291-299
[38]   A prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients [J].
Naseem, Anjum ;
Hussain, Yasser ;
Ahmad, Bashir ;
Aziz, Muhammad Tahir ;
Ahmad, Mansoor ;
Hameed, Hassan .
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2011, 61 (01) :18-22
[39]   Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients [J].
Viscoli, C ;
Cometta, A ;
Kern, WV ;
De Bock, R ;
Paesmans, M ;
Crokaert, F ;
Glauser, MP ;
Calandra, T .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (03) :212-216
[40]   Extended Versus Intermittent Infusions of Cefepime for the Treatment of Febrile Neutropenia [J].
Przybylski, Daniel J. ;
Reeves, David J. .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2018, 26 (03) :154-158